Cardiovascular Drugs Articles & Analysis
5 articles found
The evaluation of cardiovascular toxicity is a significant challenge in drug development. Preclinical evaluation of cardiovascular safety involves a multifaceted approach, encompassing a plethora of in vitro and in vivo endpoints. These assessments continuously evolve, aiming to mitigate the incidence of cardiovascular toxicity ...
For instance, altered metabolite profiles have been associated with cancer, diabetes, cardiovascular diseases, and neurodegenerative disorders. Uncover Drug Targets: Metabolomics aids in the identification of potential therapeutic targets by highlighting specific metabolites or metabolic pathways that are dysregulated in diseases. ...
Cardiovascular safety liabilities caused 52.3 % of 44 marketed data from 1980 to 2011, and cardiovascular disease remains the leading cause of death globally, yet only 8.7% of cardiovascular drugs successfully pass clinical trials. ...
HFpEF is a complex disease which accounts for more than half of all heart failure (HF) hospital admissions and is an increasing disease burden. [1] The prevalence of HFpEF is climbing, reflecting an increasingly elderly and comorbid population, as well as reinforcing the need for more effective therapies.[2] SGLT2is are a class of anti-diabetic drugs that have demonstrated large ...
Introduction “Our priority is to provide our customers with the high purity water and steam that is critical to the development and manufacturing of life-saving medications now and for future generations.” —George Gsell, MECO President Nexus Pharmaceuticals, maker of difficult-to-manufacture, high quality, FDA-approved specialty and generic drugs, is opening a $250 million, ...